Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market

Medical company HeraMED has partnered with creative agency, Meerkats to progress the launch of its medical grade foetal heart monitor, HeraBEAT.

This product allows expectant mothers to monitor their baby’s heartbeat by using a simple smartphone app.

Meerkats have worked with companies such as St John Ambulance and iiNet assisting companies by offering creativity and innovation.

With the app expected to launch in May, this partnership will provide consulting services to HeraMed’s branding, digital marketing, media strategy, and social media initiatives.

HeraMED has already partnered with two leading medical organisations to diversify its product range and services.

However, it has been revealed that the first order has already been received from Dale Group International for 250 units.

Meerkats will receive a pre-determined commission from the distributor, Dale Group International for each device sold, and HeraMED believes that this will provide a considerable validation and drive market uptake for Meerkats.

HeraMED CEO David Groberman hopes this partnership will benefit both companies.

“To have secured a partnership with an agency of Meerkats caliber is a tremendous achievement for HeraMED. However, to have Meerkats add the campaign to their Meerkats Venture approach speaks volumes about their confidence in the HereBEAT device and its potential in the Australian market,” he said.

Future products from HeraMED include the EchoBeat which monitors foetal movement and Orion, an AI powered pregnancy monitor.

Please find announcement attached here

HMD by the numbers
More From The Market Herald
Incannex Healthcare (ASX:IHL)

" Incannex Healthcare (ASX:IHL) engages Procaps to manufacture sleep apnoea treatment

Incannex Healthcare (IHL) has engaged a company to manufacture its soft-gel capsules in preparation for upcoming clinical trials.
(ASX:ATH) -

" Alterity Therapeutics (ASX:ATH) expands clinical development program

Alterity Therapeutics (ATH) is expanding the phase two clinical development program for its lead asset ATH434 in patients with Multiple System Atrophy (MSA).
Althea Group (ASX:AGH) - CEO, Joshua Fegan

" Althea Group (ASX:AGH) hits new high in sales receipts

Althea Group (AGH) brought in a new high of $4.5 million in customer receipts over the recently completed September quarter.
Singular Health Group (ASX:SHG) - Chief Operating Officer, James Hill

" Singular Health (ASX:SHG) collaborates with CSIRO and Osteopore (ASX:OSX)

Singular Health Group (SHG) will collaborate with CSIRO and Osteopore (OSX) for an artificial intelligence (AI) based tool to make patient-specific 3D cranial